Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Proteus
Generic Name
Proteus Inconstans
Active Ingredient
Proteus InconstansCategory
Calculi Dissolution Agent [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30 [hp_C]/30[hp_C] | PELLET | ORAL | 0220-4167 |
Detailed information about Proteus
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Proteus, you must consult a qualified healthcare professional.
Proteus Inconstans is a specialized therapeutic agent classified as a Calculi Dissolution Agent and Anti-coagulant. It is primarily utilized in the management of renal and biliary stones through acidifying and calcium chelating activities.
The dosage of Proteus Inconstans must be individualized based on the patient's urinary pH goals and the size/type of the calculi being treated.
Proteus Inconstans is not currently FDA-approved for use in pediatric patients under the age of 12. For adolescents aged 12 to 18, dosing is typically calculated based on body weight, starting at 2 mg/kg per day, not to exceed the standard adult dose. Clinical data in children are limited, and use in this population should be restricted to specialized pediatric urology centers.
Since Proteus Inconstans is primarily excreted by the kidneys, dosage adjustments are critical for patients with impaired renal function.
No specific dose adjustments are required for patients with mild hepatic impairment. However, in cases of severe cirrhosis (Child-Pugh Class C), the drug should be used with caution due to potential changes in protein binding and metabolism.
Geriatric patients often have a natural decline in renal function. It is recommended to start at the lower end of the dosing spectrum (e.g., 100 mg twice daily) and monitor for signs of electrolyte imbalance or excessive anticoagulation.
To ensure maximum effectiveness and safety, patients should adhere to the following guidelines:
If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects like gastric acidity or bleeding.
Signs of an overdose of Proteus Inconstans may include severe stomach pain, vomiting, metabolic acidosis (rapid breathing, confusion, lethargy), and unusual bleeding or bruising. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, involving intravenous fluids and bicarbonate therapy to correct acidosis.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to stone regrowth or rebound effects.
Most patients taking Proteus Inconstans experience mild side effects, which often diminish as the body adjusts to the medication. The most common include:
> Warning: Stop taking Proteus Inconstans and call your doctor immediately if you experience any of the following:
Prolonged use of Proteus Inconstans (greater than 6 months) may lead to the following:
Proteus Inconstans possesses significant anticoagulant activity. In patients with underlying bleeding disorders, active peptic ulcers, or those taking concurrent antiplatelet agents, there is an increased risk of life-threatening hemorrhage. Clinical monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR) is required in high-risk populations. Use with extreme caution in patients undergoing major surgery.
Report any unusual symptoms, especially those related to bleeding or severe abdominal pain, to your healthcare provider immediately.
Proteus Inconstans is a potent pharmacological agent that requires careful medical supervision. It is not a simple supplement and should never be shared with others. Patients must be aware that the process of stone dissolution can sometimes cause temporary discomfort as stone fragments (gravel) pass through the urinary tract. Maintaining high fluid intake (at least 2-3 liters per day) is the most critical safety measure a patient can take while on this therapy.
As of the 2026 FDA updates, Proteus Inconstans carries a Black Box Warning regarding the Risk of Severe Hemorrhage. This warning highlights that the drug's anticoagulant properties can exacerbate existing bleeding conditions or interact dangerously with other blood thinners. Healthcare providers must perform a baseline coagulation screen before initiating therapy and monitor for signs of occult bleeding throughout the treatment course.
Patients on Proteus Inconstans require regular laboratory follow-ups:
Proteus Inconstans generally does not cause drowsiness. However, if a patient experiences dizziness due to electrolyte changes or mild anemia from occult bleeding, they should avoid driving or operating heavy machinery until they know how the medication affects them.
Alcohol should be avoided or strictly limited while taking Proteus Inconstans. Alcohol can increase the risk of gastric irritation and dehydration, both of which counteract the therapeutic goals of the medication and increase the risk of side effects.
Do not stop taking Proteus Inconstans abruptly unless directed by a doctor. Sudden discontinuation can lead to a rapid rebound in urinary pH, which may cause minerals to precipitate quickly, potentially leading to acute stone blockage or "steinstrasse" (a column of stone fragments blocking the ureter).
> Important: Discuss all your medical conditions, especially any history of bleeding, kidney disease, or stomach ulcers, with your healthcare provider before starting Proteus Inconstans.
Certain medications must NEVER be taken with Proteus Inconstans due to the risk of severe adverse events:
Proteus Inconstans can interfere with several common laboratory tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
Proteus Inconstans must NEVER be used in the following circumstances:
In these conditions, the healthcare provider must perform a careful risk-benefit analysis:
Patients with known allergies to other non-standardized allergenic extracts (such as certain fungal or plant extracts) may be at a higher risk of reacting to Proteus Inconstans. Specifically, those with sensitivities to Gram-negative bacterial components (endotoxins) should be tested via a skin prick before starting full-dose oral therapy.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of bleeding disorders or kidney issues, before prescribing Proteus Inconstans.
FDA Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. Proteus Inconstans should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is a specific concern regarding the anticoagulant effect, which could increase the risk of placental abruption or maternal hemorrhage during delivery. Use in the third trimester is generally avoided unless the maternal condition is life-threatening.
It is unknown whether Proteus Inconstans or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (including changes in blood pH or bleeding tendencies), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients below the age of 12 have not been established. In older children, the drug is used with extreme caution because the long-term effects of chronic acidification on growing bones are not fully understood. Pediatric patients require more frequent monitoring of growth parameters and bone density.
Clinical studies of Proteus Inconstans included a significant number of subjects aged 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. The primary concern in the elderly is the age-related decline in renal function. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
As previously noted, Proteus Inconstans is contraindicated in severe renal impairment. In patients with moderate impairment, the half-life of the drug is extended from 8 hours to approximately 14 hours. This necessitates a reduction in dosing frequency (e.g., twice daily instead of three times daily) to prevent accumulation and systemic acidosis.
In patients with hepatic impairment, the primary concern is the potential for decreased production of clotting factors, which could synergize with the drug's anticoagulant effects. Close monitoring of INR is required for any patient with Child-Pugh Class B or C cirrhosis.
> Important: Special populations require individualized medical assessment and more frequent clinical monitoring to ensure safety.
Proteus Inconstans exerts its therapeutic effect through a sophisticated biochemical interaction with the urinary environment. The Acidifying Activity [MoA] is mediated by the release of hydrogen ions (H+) during the metabolic breakdown of the drug's organic components. This shift in equilibrium reduces the concentration of carbonate and phosphate ions, which are necessary for the stability of alkaline stones.
The Calcium Chelating Activity [MoA] involves the formation of a stable, ring-like structure around calcium ions. The active ligands in the extract possess multiple electron-donor atoms (typically oxygen or nitrogen) that coordinate with the Ca2+ ion. This process, known as sequestration, effectively "hides" the calcium from reacting with oxalate or phosphate, thereby stopping stone growth and allowing existing stones to dissolve into the urine stream.
The onset of urinary acidification is rapid, typically occurring within 2 to 4 hours of the first dose. However, the dissolution of a pre-existing stone is a slow process, often requiring weeks or months of continuous therapy. The duration of effect for a single dose is approximately 6-10 hours. There is no evidence of pharmacological tolerance; the drug remains effective as long as the patient adheres to the regimen.
| Parameter | Value |
|---|---|
| Bioavailability | 55% |
| Protein Binding | 70% (Albumin) |
| Half-life | 6 - 8 hours |
| Tmax | 1.5 - 2.5 hours |
| Metabolism | Hepatic (Glucuronidation) |
| Excretion | Renal 80%, Fecal 20% |
Proteus Inconstans is a member of the Calculi Dissolution Agent [EPC] class. It is unique in that it also carries the Anti-coagulant [EPC] designation. It is often grouped with other urinary acidifiers like ammonium chloride, but its chelating properties make it more similar to agents like EDTA or citric acid, albeit with a biological origin.
Common questions about Proteus
Proteus Inconstans is primarily used as a Calculi Dissolution Agent to help break down and dissolve kidney stones, particularly those that are alkaline in nature like struvite or calcium phosphate stones. It works by lowering the pH of the urine and binding to calcium ions to prevent them from forming hard deposits. Additionally, it has anticoagulant properties, which may be used to prevent blood clots in patients undergoing renal procedures. Some healthcare providers also use it as an allergenic extract for diagnostic testing in specialized clinics. It is a comprehensive treatment for patients who cannot undergo surgery for their stones.
The most frequently reported side effects include gastrointestinal issues such as nausea, stomach upset, and mild diarrhea, which occur because the medication is an acidifying agent. Patients may also experience an increased frequency of urination as the body works to flush out dissolved stone fragments. A metallic or sour taste in the mouth is another common complaint reported by about 10% of users. Most of these symptoms are mild and tend to resolve as the body becomes accustomed to the medication. However, if these symptoms become severe or persistent, you should contact your healthcare provider.
It is strongly recommended that you avoid or significantly limit alcohol consumption while taking Proteus Inconstans. Alcohol can irritate the stomach lining, which, when combined with the acidifying effects of the drug, significantly increases the risk of gastritis or ulcers. Furthermore, alcohol is a diuretic that can lead to dehydration, making it harder for the kidneys to flush out the dissolved stone particles. Dehydration also increases the risk of the drug becoming too concentrated in the kidneys, potentially leading to toxicity. Always prioritize hydration with water over alcoholic beverages during your treatment.
Proteus Inconstans is classified as FDA Pregnancy Category C, meaning it should only be used if the potential benefits outweigh the risks to the fetus. There is limited data on human pregnancy, but the drug's anticoagulant properties pose a significant risk of bleeding complications for both the mother and the developing baby. It could potentially interfere with the normal development of the fetal skeletal system due to its calcium-chelating effects. If you are pregnant or planning to become pregnant, you must discuss alternative stone management strategies with your doctor. Most physicians will avoid prescribing this medication during the third trimester.
While the medication begins to acidify the urine within just a few hours of the first dose, the actual dissolution of a kidney stone is a gradual process. Most patients will not see a significant reduction in stone size on imaging tests for at least 4 to 8 weeks. The total duration of treatment depends on the size and composition of the stone; some large stones may require 6 months or more of continuous therapy. It is vital to continue taking the medication exactly as prescribed, even if you do not feel immediate relief. Regular follow-up appointments with ultrasound or CT scans will be used to monitor your progress.
You should never stop taking Proteus Inconstans suddenly without consulting your healthcare provider. Abruptly halting the medication can cause the urine pH to rise rapidly, which may lead to a "rebound" effect where minerals quickly crystallize and form new stones or cause existing fragments to clump together. This can result in a sudden blockage of the urinary tract, causing severe pain and requiring emergency intervention. If the medication needs to be stopped, your doctor will usually provide a tapering schedule or switch you to a different therapy to ensure a safe transition. Always follow the professional guidance provided by your urologist.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed dose and simply take the next one at the regular time. Never take two doses at once to make up for a missed one, as this can lead to excessive acidity in the stomach or an increased risk of bleeding due to the drug's anticoagulant effects. Maintaining a consistent level of the drug in your system is important for effective stone dissolution. Setting a daily alarm can help you stay on track with your multi-dose schedule.
Weight gain is not a recognized side effect of Proteus Inconstans. The medication does not affect metabolic rate or appetite in a way that typically leads to increased body fat. However, some patients might experience mild fluid retention or bloating if their kidney function is not optimal while on the drug. If you notice a sudden, significant increase in weight or swelling in your legs and ankles, this could be a sign of kidney stress rather than simple weight gain. You should report any such changes to your doctor immediately for a full evaluation of your renal health and electrolyte balance.
Proteus Inconstans has several significant drug interactions, particularly with other blood thinners like warfarin and certain diuretics. Because it is an acidifier and a chelator, it can also change how other drugs are absorbed or excreted by the kidneys. For example, it can reduce the effectiveness of certain antibiotics if taken at the same time. It is crucial to provide your doctor with a complete list of all medications, including over-the-counter drugs and herbal supplements like St. John's Wort. Your pharmacist can help you create a dosing schedule that minimizes the risk of these interactions.
As of 2026, Proteus Inconstans is primarily available as a branded biological extract, though some generic versions of the non-standardized extracts have begun to enter the market. Because it is a complex biological product, generic versions must undergo rigorous testing to ensure they have the same acidifying and chelating potency as the original. Availability may vary depending on your region and insurance coverage. You should check with your pharmacist to see if a lower-cost generic equivalent is available for your specific prescription. Always ensure that any generic version is FDA-approved for the same indications.